Noor Ul Ain Rehman
Thu, May 14, 2026 astatine 11:50 AM CDT 2 min read
The standing update came aft Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its fiscal Q1 2026 results, reporting a full gross of $64.9 cardinal for the quarter, reflecting a 224% year-over-year increase. Revuforj® nett gross was $48.9 million, showing enactment successful menin inhibition and expanding uptake successful R/R NPM1m AML. In addition, Niktimvo™ nett gross reached $55.1 cardinal successful the quarter, resulting successful Syndax collaboration gross of $15.9 million. The institution besides reported that it expects caller revumenib real-world, frontline, and post-HSCT attraction information successful fiscal Q2 2026, on with topline information anticipated successful fiscal Q4 2026 from Phase 2 trials of axatilimab successful IPF and recently diagnosed chronic GVHD.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is progressive successful the improvement of crab therapies, which its products including SyndAccess, Revuforj, Niktimvo, and IncyteCARES.
While we admit the imaginable of SNDX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
3





English (CA) ·
English (US) ·
Spanish (MX) ·